CVALF
Price
$1.97
Change
-$0.05 (-2.48%)
Updated
May 22 closing price
Capitalization
53.41M
GNFT
Price
$4.21
Change
-$0.14 (-3.22%)
Updated
May 23, 03:14 PM (EDT)
Capitalization
228.1M
122 days until earnings call
Interact to see
Advertisement

CVALF vs GNFT

Header iconCVALF vs GNFT Comparison
Open Charts CVALF vs GNFTBanner chart's image
Covalon Technologies
Price$1.97
Change-$0.05 (-2.48%)
Volume$9.8K
Capitalization53.41M
Genfit SA
Price$4.21
Change-$0.14 (-3.22%)
Volume$200
Capitalization228.1M
CVALF vs GNFT Comparison Chart
Loading...
View a ticker or compare two or three
VS
CVALF vs. GNFT commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVALF is a Hold and GNFT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (CVALF: $1.97 vs. GNFT: $4.35)
Brand notoriety: CVALF and GNFT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVALF: 160% vs. GNFT: 2%
Market capitalization -- CVALF: $53.41M vs. GNFT: $228.1M
CVALF [@Biotechnology] is valued at $53.41M. GNFT’s [@Biotechnology] market capitalization is $228.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVALF’s FA Score shows that 0 FA rating(s) are green whileGNFT’s FA Score has 1 green FA rating(s).

  • CVALF’s FA Score: 0 green, 5 red.
  • GNFT’s FA Score: 1 green, 4 red.
According to our system of comparison, CVALF is a better buy in the long-term than GNFT.

Price Growth

CVALF (@Biotechnology) experienced а +8.45% price change this week, while GNFT (@Biotechnology) price change was +9.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

GNFT is expected to report earnings on Sep 22, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
GNFT($228M) has a higher market cap than CVALF($53.4M). GNFT has higher P/E ratio than CVALF: GNFT (128.17) vs CVALF (15.25). GNFT YTD gains are higher at: 17.093 vs. CVALF (-11.884).
CVALFGNFTCVALF / GNFT
Capitalization53.4M228M23%
EBITDA5.98MN/A-
Gain YTD-11.88417.093-70%
P/E Ratio15.25128.1712%
Revenue34.7MN/A-
Total Cash17.5MN/A-
Total Debt785KN/A-
FUNDAMENTALS RATINGS
CVALF vs GNFT: Fundamental Ratings
CVALF
GNFT
OUTLOOK RATING
1..100
273
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
4694
PRICE GROWTH RATING
1..100
4043
P/E GROWTH RATING
1..100
942
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (63) in the null industry is in the same range as GNFT (84) in the Biotechnology industry. This means that CVALF’s stock grew similarly to GNFT’s over the last 12 months.

CVALF's Profit vs Risk Rating (67) in the null industry is somewhat better than the same rating for GNFT (100) in the Biotechnology industry. This means that CVALF’s stock grew somewhat faster than GNFT’s over the last 12 months.

CVALF's SMR Rating (46) in the null industry is somewhat better than the same rating for GNFT (94) in the Biotechnology industry. This means that CVALF’s stock grew somewhat faster than GNFT’s over the last 12 months.

CVALF's Price Growth Rating (40) in the null industry is in the same range as GNFT (43) in the Biotechnology industry. This means that CVALF’s stock grew similarly to GNFT’s over the last 12 months.

GNFT's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CVALF (94) in the null industry. This means that GNFT’s stock grew significantly faster than CVALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LGPSX34.97N/A
N/A
ProFunds Large Cap Growth Svc
RPMFX15.06N/A
N/A
Reinhart Genesis PMV Advisor
MAMEX20.11N/A
N/A
MoA Mid Cap Equity Index Fund
EAMAX17.26N/A
N/A
Lord Abbett Emerging Markets Equity A
JGMRX22.02-0.08
-0.36%
Janus Henderson Triton R

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
-2.26%
SMMT - CVALF
27%
Poorly correlated
+1.42%
GNFT - CVALF
25%
Poorly correlated
N/A
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
N/A
MBIO - CVALF
20%
Poorly correlated
+7.56%
More

GNFT and

Correlation & Price change

A.I.dvisor tells us that GNFT and CVALF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNFT and CVALF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNFT
1D Price
Change %
GNFT100%
N/A
CVALF - GNFT
25%
Poorly correlated
-2.26%
ORMP - GNFT
25%
Poorly correlated
N/A
GLTO - GNFT
25%
Poorly correlated
N/A
CAPR - GNFT
24%
Poorly correlated
-2.34%
FENC - GNFT
24%
Poorly correlated
-3.86%
More